Pharma: Other News To Note

• Pfizer Inc., of New York, said the FDA approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML). The drug is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome-positive CML who are resistant to or who cannot tolerate other therapies, including Gleevec (imatinib, Novartis AG).